Multicentre and single centre clinical trials share methodological problems which are well known (box). Multicentre trials do, however, have several distinct advantages. They provide:
(a) larger sample size so that the result is more precise, appropriate subgroup analysis is more feasible, and there is a lower risk of an apparently "negative" result when the treatment is, in truth, effective;
(b) quicker results before people lose scientific and commercial interest in the treatment and before it is modified or the theoretical indications for it are changed; (c) wider dissemination of the results and, possibly, more widespread belief in their validity;
(d) standardised definitions of disease and measurements of outcome among centres and among countries in international trials; (e) a wider range of clinical and methodological skills to solve protocol problems;
(f) usually a wider range of patients, facilitating the generalisation of results, which can be broadly applied to future patients in other centres and other countries; (g) large negative trials which are more likely to be published than small negative trials. This is important otherwise small positive trials, which are more likely to be submitted for publication and probably more likely to be accepted rather than small negative trials, will tend to dominate the scientific literature; (h) less suspicion and rivalry among centres and countries without necessarily suppressing healthy competition; (i) less scientific isolation; (I) better national and international collaboration; (k) facilitation of further multicentre trials of potentially important treatments, provided that the initial trial is not too demanding.
The difficulties of multicentre trials compared with single centre trials mainly concern the coordination of many people in several centres and even countries (see box on next page). There are usually several possible solutions, the best depending on circumstances, geography, number of centres, budget, and so on. What follows is not meant to be an ossified blueprint but some suggestions. Suggestions, moreover, which have not been tested in randomised trials but which, at least, are based on some experience. surprisingly expensive. Fortunately, if it is written in English translation is now hardly necessary, at least not in Western Europe, which is a huge advantage to us in Great Britain and a great credit to our medical colleagues on the continent.
Finding the centres
Having accepted that a multicentre rather than a single centre trial is scientifically necessary to solve a particular treatment problem, friends and colleagues from a few centres usually get together to discuss a protocol. From there, other friends and colleagues are brought in from centre to centre and from country to country until enough centres are found to satisfy the sample size requirements in a reasonable period of time. After about three years recruitment gets tedious and may fall off, but follow up is usually less time consuming and may need to continue much longer, depending on the treatment. Key people in a country are often very successful in recruiting their own compatriots, far more so than an outsider. Advertising in medical journals and through specialist organisations can also help.
Pharmaceutical companies may, through their national and international networks, approach numerous potential collaborators simultaneously. However the centres are found, they must be seriously interested and reasonably competent in the field but not necessarily specialists. In any event specialists may already be involved in their own competing studies; relative non-specialists in district general hospitals or general practice may be extremely keen to collaborate -and make very effective collaborators. Usually they have more patients than teaching hospitals; they may have no other way to take part in medical research, and to be involved with specialists in the field who are organising the trial is often educative. But whoever the collaborators are, they are all equal when it comes to recruiting patients, and it is their trial not the principal investigators' whose role is organisational and catalytic: there should be no "star billing."
Randomisation
Randomisation must be centralised and is best done by telephone or perhaps by a computer link to some central point which may be the trial office or, if 24 hour cover is required, a hospital ward or switchboard. This is the only way for the trial organisers to Written forms should be no longer than one side of A4 paper; if they are they probably will not be completed fully or reliably. In any event trials should not interfere with routine clinical practice.
Trial coordinator
This is the key person even if the trial is not large enough to merit a full time appointment. The job is administrative, not medical. She, for it is seldom he, stands at the centre of the trial and must be committed, energetic, sensible, well organised, have some knowledge of computing, and be able to work flexible hours. To collect the data, organise them, and transmit them to the statistician she must be meticulous and even obsessional, but she must also be good with people so that she can run the trial office and maintain harmonious relationships with the distant collaborators. She must be adroit at dealing with the awkward (and some doctors can be remarkably awkward) and flexible and energetic enough so that she can hop on and off trains and planes and put up with a certain amount of discomfort as she travels from centre to centre extracting data from forgetful collaborators, encouraging them to randomise more patients, and generally nurturing esprit-de-corps, while still retaining a sense of humour.
Trial office
The trial office, organised and supervised by the trial coordinator, has the task of collecting, checking, and entering the data from the distant centres and requesting more information ifthere are inconsistencies or omissions. The office must supply the collaborators with all the necessary documentation (entry and follow up forms, freepost envelopes, sticky labels, etc), and possibly even the trial medication, dispatch regular newsletters and listings on missing data, listings of when patients are due for their next follow up, and answer questions from the many centres. The office must be available, friendly, helpful, knowledgeable, reliable, and efficient, perhaps in more than one language for international trials; although doctors may speak excellent English, the same does not necessarily BMJ VOLUME 300 20 JANUARY 1990 Issues 
Quality control
In a single centre trial it is important that the trial treatment is properly described, well delivered, and any complications fairly assessed. This is even more important in multicentre trials, when there are certain to be differences among centres, both real and due to chance. Even drug treatment may differ among centres because of different storage conditions or possibly circumstances of delivering it to the patients. But of more concern is variation among centres in other non-drug treatments being evaluated such as surgery, speech therapy, psychotherapy, etc. Obviously all the centres must agree to standardise more or less such treatments so that about the same amount is given for about the same time and that it is reasonably uniform. Such non-drug treatments, however, will never be exactly the same in all centres and it is counterproductive to insist that they are; as long as they are roughly similar no problems will arise and the trial result will be applicable to other centres giving roughly, but never exactly, the same treatment. Monitoring uniformity of treatment is difficult but at least it helps to monitor any immediate complications, such as postoperative morbidity, and to have regular meetings of the collaborators. If a centre is performing badly (inadequate treatment, excessive complications, not enough patients to ensure competence, etc) then it should stop randomising patients, but not, of course, stop following up those already randomised. Clinically sensible cointerventions, such as drug regimens administered during a trial of a surgical procedure, do not have to be exactly the same in each centre because randomisation (stratified by centre if necessary) will ensure that they are used in the same proportion of "treated" and "control" patients across the trial participants.
Cost
Multicentre trials are expensive but they need not be prohibitively so provided that collaborators are reasonable and do not attempt to re-equip their entire department and undertake major non-trial projects at the expense of a sponsoring pharmaceutical company. Indeed, from the point of view of unit cost per patient randomised or per patient year of follow up multicentre trials should be cheaper than single centre trials as they gain from economies of scale. But, of course, the trial office and collaborators' meetings must be properly funded and the collaborators themselves reimbursed for any extra work (which is very little in a well designed trial) over and above routine clinical practice. There are various ways of doing this: a lump sum per patient randomised; a sum per complete data form received by the trial office; a formula based on the number of patients randomised to support a research nurse, etc. Whatever is done the collaborators should be paid only for extra work done and not work that they say they will do. In many trials, however, it is difficult to obtain proper funding; this applies particularly to treatments from which no profits are to be made-for example, non-patented drugs, surgery, physiotherapy-so that it is totally inappropriate for trial funding to be left entirely to the pharmaceutical industry. Although a sponsoring company must not be concerned in either data analysis or publication, it can be extremely helpful in collecting BMJ VOLUME 300baseline (but not outcome) data, maintaining trial discipline, and encouraging recruitment through its own networks of medical representatives and researchers. Whatever the cost of a trial, it should be compared with the cost of the disease being treated and, perhaps, against the cost of non-medical endeavours such as low altitude military aircraft training or unemployment benefit. By any such comparisons multicentre trials are usually extremely inexpensive and may lead to the rejection of expensive but ineffective treatments-for example, extracranial to intracranial bypass surgery for the prevention of stroke-and not always to the introduction of more expensive health care.
Writing the papers
Like the protocol, this is a job for the principal investigator, not a committee. Naturally, it will be necessary to have many discussions with the trial statistician and trial coordinator and comments and advice from all the collaborators as numerous drafts are produced. It is crucial, however, that in the end all the results are published under the name of all the collaborators; without them there would have been no trial at all, and they did the work. Although currently unfashionable in some quarters, the whole philosophy underlying multicentre trials is that group effort takes precedence over individual effort; only by acting as a group can the individuals get answers to therapeutic questions which affect their own individual patients. Of course, any centre can publish its own results but there must be no "star billing" for authors when the results of the whole trial are presented.
Conclusions
Before Fibromuscular dysplasia of the renal arteries is usually associated with hypertension, but occasionally it may present with acute loin pain due to occlusion of the renal arteries or embolisation of small peripheral vessels. The presenting symptoms may then be indistinguishable from acute calculous obstruction or acute pyelonephritis. Early diagnosis of arterial occlusion is essential to prevent permanent damage to the kidney.
We report on three young previously fit patients who presented with acute loin pain, in whom renal infarction occurred in relation to fibromuscular dysplasia of the renal arteries. We also discuss how patients with loin pain should be investigated so that arterial occlusion can be diagnosed early.
Case 1
A 33 year old man was admitted with a four hour history of acute right testicular pain. Testicular torsion was diagnosed initially, but an exploratory operation disclosed no abnormality. Two days after admission he was still in pain, which had moved to the right loin, and he developed frank haematuria. Investigations disclosed a raised white cell count (20 7 x lO9/1) but normal plasma urea and electolyte concentrations. Microscopic examination of the urine showed increased numbers of red and white cells and granular casts. Culture of his urine gave negative results. On intravenous urography the right kidney was thought to be non-functioning. On ultrasonography the size of the kidney was normal with no dilatation of the pelvicaliceal system. Ureteric obstruction due to a radiolucent calculus was diagnosed, and he was treated conservatively.
The next day he developed a temperature of 38°C, and despite 24 hour treatment with intravenous antibiotics he did not improve. A right retrograde pyelogram was normal, but a 99Tc diethylenetriaminepenta-acetate (99Tc DTPA) renogram showed that there was no perfusion of the right kidney. Renal angiography showed that the right renal artery was completely occluded by thrombus 3 cm from its origin; there was some irregularity of the wall of the left main renal artery, and two stenoses were seen in one of the segmental vessels. The findings were consistent with a diagnosis of fibromuscular dysplasia. Despite the five day interval after the onset of symptoms we attempted to revascularise the kidney with intra-arterial streptokinase 5000 units/hour. The thrombus in the right main renal artery was dissolved, disclosing a 75% stricture, which was treated with balloon angioplasty. Unfortunately pericatheter thrombus formed, which embolised distally, and peripheral perfusion to the kidney could not be restored. The patient was given long term anticoagulant treatment and discharged. Detailed investigation subsequently failed to disclose BMJ VOLUME 300 20 JANUARY 1990
